If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
184
results.
Updated on
22/10/2026 [11:17:00]
Results 125 to 150 of 184
Absstract of: WO2026188235A1
The present disclosure relates to methods of preventing and/or treating neuroinflammation in a subject in need thereof. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., Amyotrophic lateral sclerosis (ALS)) in vitro. The methods comprise administering one or more Angiotensin II Receptor I Blocker (ARB) to the subject. The present disclosure also relates to methods and systems for modeling aging related neurodegenerative diseases (e.g., ALS) in vitro.
Absstract of: WO2026185106A1
The present invention relates to the use of a pharmaceutical combination comprising molecules that rebilance the pathway of the epigenetic modulators LiN28, EZH2 and Let-7 and increases the expression of GFAP protein in particular in the treatment of all the diseases of the central nervous system (CNS) wherein LiN28, EZH2 and Let-7 dysregulation influence the expression of GFAP gene, selected from Huntington's disease, Amyotrophic Lateral Sclerosis (ALS), Schizophrenia, Bipolar Disorder, Fetal alcohol spectrum disorder and Autism. The invention further relates to the use of a pharmaceutical composition comprising said combination and at least one pharmaceutical acceptable excipient in the treatment and/or prevention of neurodegenerative diseases and neurodevelopment diseases.
Absstract of: WO2026183787A1
Provided is a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of amyotrophic lateral sclerosis represented by the following Formula (I). Also provided is a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt, hydrate or solvate thereof for use in the treatment of amyotrophic lateral sclerosis.
Absstract of: MX2026007638A
Described are compounds, compositions of polycyclic, water soluble and a dual acting nitroxide substituted compounds and methods useful as mitogen-activated protein (MAP) kinase-interacting kinases1 and 2 (MNK1 and MNK2) inhibitors, for the treatment of cancer, Alzheimer's disease, autism, fragile X syndrome, obesity and fat cell associated diseases such as liposarcoma, MASH, MAFLD, sarcopenic obesity and polycystic ovary syndrome, and a method for treating, preventing, or mitigating the effects of a migraine or symptoms related to a migraine and a nerve pain.
Absstract of: MX2026007157A
Aspects of the disclosure relate to compositions and methods for the diagnosis and/or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as amyotrophic lateral sclerosis (ALS). In some embodiments, the disclosure relates to recombinant adeno-associated viruses (rAAVs) expressing antibodies and antigen-binding fragments thereof that bind to poly(GA) RAN proteins. In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof the rAAVs.
Absstract of: WO2026183555A1
Methods of treating a neurodegenerative disease in a subject in need thereof are provided. Exemplary methods include providing a biological sample from the subject; measuring an NfL530 peptide concentration in the biological sample; measuring at least one of an NfL284 peptide concentration and an NfL101 peptide concentration in the biological sample; determining at least one of an NfL530/NfL284 ratio and an NfL530/NfL101 ratio; and treating the subject based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio. In some embodiments, the biological sample is selected from whole blood, plasma, and cerebrospinal fluid. In some embodiments, the subject is determined to have ALS based on the determined NfL530/NfL284 and/or NfL530/NfL101 ratio.
Absstract of: WO2026183116A2
The present disclosure provides, among other things, methods for restoring neuronal cell function in a subject having a brain-related disorder and methods for improving one or more brain functions in a subject with Alzheimer's Disease (AD) or a subject that has suffered from an acute central nervous system (CNS) injury. Such methods can comprise administering to the subject one or more peptide inhibitors of Ca2+/calmodulin-dependent protein kinase II (CaMKII). The present disclosure also provides a composition comprising one or more peptide inhibitors of Ca2+/Calmodulin-Dependent Protein Kinase II (CaMKII inhibitor peptides).
Absstract of: US20260256960A1
Novel lysosomal acid lipase (LAL) positron emission tomography ligands are provided. Also disclosed herein are methods of assessing the risk of developing Alzheimer's disease (AD) or Alzheimer's Disease Related Dementias (ADRD) and methods of diagnosing AD/ADRD in a subject comprising measuring levels of LAL and optionally LAL accumulation in the subject. Methods of treatment comprising administering LAL are also provided.
Absstract of: US20260256860A1
A traditional Chinese medicine composition for treating amyotrophic lateral sclerosis and the use thereof. The composition is prepared by means of combining Ginseng radix et rhizoma and Cistanches herba.
Absstract of: US20260256745A1
0000 Fenbendazole offers a cure for Diabetes. The glucose levels in diabetes can be normalized by clearing tau and microtubules, resulting in clearing of Hyperglycemia. Hyperglycemia refers to high blood glucose readings, taken from the blood vessels. The glucose is having difficulty passing into some cells through thick microtubules. As seen in recent High Resolution Microscopy: hundreds or thousands of microtubules can be found in a single problematic cell. “during diabetes, microtubules are much denser inside beta cells.” By clearing excess tau oligomers and microtubules, Fenbendazole normalizes the glucose levels. Parkinson's disease also has Hyperglycemia and excess tau oligomers. “tau aggregation correlates with motor deficits and degeneration of dopamine-producing regions of the brain” in Parkinson's. Retinal manifestations of Tau or Amyloid are a biomarker. From the eyes, Tau has been known to proliferate through nerve cells, reaching the brain.
Absstract of: WO2026179739A1
Disclosed in the present invention are an aminothiazole compound and use thereof as a brain-permeable histamine H2 receptor agonist, which belong to the field of medicine. The aminothiazole compound provided in the present invention has a general structural formula represented by formula (I) and comprises a pharmaceutically acceptable salt. The aminothiazole compound of the present invention has histamine H2 receptor agonist activity and excellent blood-brain barrier permeability. Therefore, the aminothiazole compound can be used in the preparation of a medicament for treating schizophrenia, mania, attention deficit hyperactivity disorder, binge eating disorder or bulimia nervosa, autism, Parkinson's disease, ischemic brain injury, and other diseases.
Absstract of: US20260256865A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, comprising, as an active ingredient, a mulberry fruit extract fermented with lactic acid bacteria. The mulberry fruit extract fermented with lactic acid bacteria improves memory and cognitive function, and thus can exhibit excellent effects on preventing, alleviating or treating Alzheimer's disease.
Absstract of: WO2026183114A2
The present disclosure provides, among other things, methods for restoring neuronal function in a subject in need thereof, methods for treating a subject with Alzheimer's Disease (AD) or a subject that has suffered from an acute central nervous system (CNS) injury, and methods for improving one or more brain functions in a subject in need thereof. Such methods can comprise administering to the subject one or more peptide inhibitors of Ca2+/calmodulin-dependent protein kinase II (CaMKII).
Absstract of: US20260256889A1
0000 Disclosed herein is a liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist and a cyclodextrin comprising hydroxypropyl substitutions. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; cardiovascular diseases, non-alcoholic steatohepatitis (NASH) and cognitive impairment, such as that caused by Alzheimer's disease.
Absstract of: MX2026008973A
Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Absstract of: US20260256755A1
Disclosed are novel strategies for the treatment of patients with Parkinson's disease and other primary and secondary Parkinsonian disorders by enhancing cell engraftment. Cell viability, engraftment, proliferation, migration, or differentiation of administered DA neuronal cells is enhanced by treating the patient with an antilipemic agent and/or a CSF-1R antagonist before, during and/or after transplantation of DA neuronal cells.
Absstract of: WO2025089370A1
Disclosed are pyrazolopyridine or pyrazolopyrimidine compounds, or salts thereof, with colony-stimulating factor-1 receptor (CSF1R) inhibitory activity, medical use thereof for treating, preventing, and/or diagnosing diseases associated with CSF1R, and methods of preparing said compounds, or salts thereof. Provided include a compound represented by Formula I, or a salt thereof, wherein R1 is hydrogen, etc.; R21 and R22 are hydrogen, or R21 and R22 together with the adjacent heterocyclic form a bridged bicyclic ring; R3 is -L31-R31 optionally substituted with one or more R32, or R31 optionally substituted with one or more R32; L31 is -C(=O)-, etc.; R31 is C1-6 alkyl, etc.; R32 is each independently halogen, etc.; and X is CR1 or N; medical use thereof, and methods of preparation thereof.
Absstract of: EP4799693A2
The present invention provides methods for treating OFF episodes in a Parkinson's Disease patient comprising administering levodopa to the pulmonary system of a patient wherein after administration, the patient's Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 score is improved by, for example, at least about 5 points compared to placebo control and/or as compared to the patient's UDPRS Part 3 score prior to administration. The invention also provides methods of reducing mean daily OFF time in a Parkinson's patient.
Absstract of: US20250127867A1
The application describes a phosphorylated tau targeted active immunotherapy to treat preclinical Alzheimer's Disease.
Absstract of: WO2025087971A1
The invention relates to the treatment of Alzheimer's disease in a human patient, said treatment comprising administration of an anti-Aβ antibody component and co-administration of edaravone, the anti-Aβ antibody component being selected from anti-Aβ antibody, an Aβ- binding fragment of an Aβ antibody, a vectorised anti-Aβ antibody and a vectorised Aβ- binding fragment of an Aβ antibody.
Absstract of: WO2020102628A1
The present disclosure relates to compositions of levodopa 4'-monophosphate and carbidopa 4'-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.
Absstract of: WO2025154076A1
This invention provides a method of prolonging the survival of subjects afflicted with ALS by administering a composition comprising pridopidine or pharmaceutically acceptable salt thereof.
Absstract of: WO2025158056A1
The invention relates to the technical field of treating Parkinson's disease. In particular, the invention relates to a particular biocompatible composition comprising a solution, and heterogeneous cellular elements suspended in said solution, of hyaluronic acid and/or carboxymethyl cellulose (CMC), and at least one biocompatible density agent, and/or at least one modified form of one or more of these molecules.
Absstract of: WO2025151884A1
The present invention is directed to methods and compositions for the administration of sodium pentosan polysulfate and related glycosaminoglycans, particularly by oral administration, particularly in combination with administration of an intestinal penetration agent. The methods and compositions are suitable for treatment of neurodegenerative diseases such as, but not limited to, Alzheimer's disease. Methods and compositions according to the present invention can be used together with other agents suitable for treatment of neurodegenerative diseases such as, but not limited to, Alzheimer's disease.
Nº publicación: CN122652060A 28/08/2026
Applicant:
GUANGDONG MEDICAL UNIV
\u5E7F\u4E1C\u533B\u79D1\u5927\u5B66
Absstract of: CN122652060A
The invention discloses a marker combination for diagnosing Alzheimer's disease as well as application and a kit thereof. The marker comprises STMN1 protein, STMN1 mRNA and hsa-miR-9-5p in peripheral blood, the content of the STMN1 protein, the content of the STMN1 mRNA and the content of miRNAhsa-miR-9-5p of a targeted STMN1 gene in the peripheral blood sample are detected, data are input into a diagnosis model obtained through Logistic regression fitting training in advance, and accurate screening and definite diagnosis of the Alzheimer's disease can be achieved. Compared with invasive detection schemes of cerebrospinal fluid and the like, peripheral blood sampling is adopted, operation is easy and convenient, the detection cost is lower, and the method is suitable for clinical large-scale non-invasive screening.
BOPI
Electronic site
